Literature DB >> 23165953

Increased risk of breast cancer in women with NF1.

Sara Aileen Madanikia1, Amanda Bergner, Xiaobu Ye, Jaishri O'Neill Blakeley.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder associated with increased risk for neoplasms. Two studies in the United Kingdom have indicated that women with NF1 (particularly women under 50) may also be at increased risk of breast cancer. No such study has been done to date in the United States. Chart review for breast cancer diagnoses was undertaken for 126 women with NF1 followed at Johns Hopkins who were 20 years of age or older. Four of 126 women who met eligibility criteria were diagnosed with breast cancer (3.2% over 15 years). The unadjusted standardized incidence ratio (SIR) for breast cancer in the NF1 population between the ages of 20 and 49 was 2.68 (P = 0.076, 95% CI 0.68-7.29) based on incidence rates of breast cancer in the general population taken from the Surveillance Epidemiology and End Results (SEER) database. The unadjusted SIR for women with NF1 ≥50 was 0.81 (P = 0.84, 95% CI 0.041-4.01). When adjusted for race, the rate of NF1 in the general population and time of diagnosis, the SIR was 4.41 (P = 0.0049, 95% CI 1.12-12.00) for women <50 versus 0.94 (P = 0.95, 95% CI 0.047-4.65) for women ≥50. The trend of a higher-than-expected number of breast cancer cases in women <50 with NF1 agrees with the prior studies from the literature. Cumulatively, the data suggests an increased risk of breast cancer for women with NF1 < 50 years old, implying a need for closer surveillance and the establishment of screening guidelines for this patient population.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23165953      PMCID: PMC3507419          DOI: 10.1002/ajmg.a.35550

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  21 in total

1.  Pulmonary hypertension in patients with neurofibromatosis type I.

Authors:  David Montani; Florence Coulet; Barbara Girerd; Mélanie Eyries; Emmanuel Bergot; Hervé Mal; Giuseppina Biondi; Claire Dromer; Thomas Hugues; Charles Marquette; Caroline O'Connell; Dermot S O'Callaghan; Laurent Savale; Xavier Jaïs; Peter Dorfmüller; Hugues Begueret; Laurent Bertoletti; Olivier Sitbon; Christine Bellanné-Chantelot; Gérard Zalcman; Gérald Simonneau; Marc Humbert; Florent Soubrier
Journal:  Medicine (Baltimore)       Date:  2011-05       Impact factor: 1.889

2.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

3.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

4.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

5.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

Review 6.  Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.

Authors:  Vincent Michael Riccardi
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-01

7.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

8.  Gynaecomastia, neurofibromatosis and breast cancer.

Authors:  Colin H Wilson; Clive D M Griffith; Josie Shrimankar; Fiona Douglas
Journal:  Breast       Date:  2004-02       Impact factor: 4.380

Review 9.  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.

Authors:  Hilde Brems; Eline Beert; Thomy de Ravel; Eric Legius
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

10.  A prospective study of neurofibromatosis type 1 cancer incidence in the UK.

Authors:  L Walker; D Thompson; D Easton; B Ponder; M Ponder; I Frayling; D Baralle
Journal:  Br J Cancer       Date:  2006-06-20       Impact factor: 7.640

View more
  35 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1.

Authors:  Ye Won Jeon; Ra Mi Kim; Seung Taek Lim; Hyun Joo Choi; Young Jin Suh
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

3.  Metaplastic Carcinoma of Breast and Neurofibromatosis 1: A Rare Association.

Authors:  Gnanapriya Vellaisamy; Suravi Mohanty; Pritilata Rout; Suraj Manjunath
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep

4.  Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.

Authors:  Heidi S Lumish; Hallie Steinfeld; Carrie Koval; Donna Russo; Elana Levinson; Julia Wynn; James Duong; Wendy K Chung
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

Review 5.  The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations.

Authors:  Sarah Macklin; Jennifer Gass; Ghada Mitri; Paldeep S Atwal; Stephanie Hines
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

6.  Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.

Authors:  Ze-Yi Zheng; Meenakshi Anurag; Jonathan T Lei; Jin Cao; Purba Singh; Jianheng Peng; Hilda Kennedy; Nhu-Chau Nguyen; Yue Chen; Philip Lavere; Jing Li; Xin-Hui Du; Burcu Cakar; Wei Song; Beom-Jun Kim; Jiejun Shi; Sinem Seker; Doug W Chan; Guo-Qiang Zhao; Xi Chen; Kimberly C Banks; Richard B Lanman; Maryam Nemati Shafaee; Xiang H-F Zhang; Suhas Vasaikar; Bing Zhang; Susan G Hilsenbeck; Wei Li; Charles E Foulds; Matthew J Ellis; Eric C Chang
Journal:  Cancer Cell       Date:  2020-03-05       Impact factor: 31.743

Review 7.  Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications.

Authors:  Eugenia Yiannakopoulou
Journal:  Cell Oncol (Dordr)       Date:  2013-12-04       Impact factor: 6.730

8.  Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.

Authors:  Fergus J Couch; Hermela Shimelis; Chunling Hu; Steven N Hart; Eric C Polley; Jie Na; Emily Hallberg; Raymond Moore; Abigail Thomas; Jenna Lilyquist; Bingjian Feng; Rachel McFarland; Tina Pesaran; Robert Huether; Holly LaDuca; Elizabeth C Chao; David E Goldgar; Jill S Dolinsky
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

9.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

10.  Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.

Authors:  Kristy Lee; Bryce A Seifert; Hermela Shimelis; Rajarshi Ghosh; Stephanie B Crowley; Natalie J Carter; Kurston Doonanco; A Katherine Foreman; Deborah I Ritter; Sharisse Jimenez; Mackenzie Trapp; Kenneth Offit; Sharon E Plon; Fergus J Couch
Journal:  Genet Med       Date:  2018-12-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.